HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spiked Supplements, Drug-Claim Cosmetics And Medical Food On Recall

This article was originally published in The Rose Sheet

Executive Summary

Recent recalls classified by FDA include products marketed as supplements but spiked with an ED drug and marketed in Asian groceries in NJ and NY; Flawless Beauty's cosmetics FDA deemed drugs; and Primus Pharmaceuticals' medical food the agency said could cause a risk of potentially fatal condition.

You may also be interested in...



More Undeclared Allergens, Contaminated Kratom Prompt Supplement Recalls

Recalls by AdvoCare International and Independent Nutrition increase to seven the number of supplement recalls announced in 2018 after FDA, officials in state health agencies or manufacturers determined the products contained nut or milk ingredients not listed on labels. Latest recall of kratom supplements potentially contaminated with salmonella is by Club 13, which had distributed pouches and bottles of its namesake kratom Maeng Da Red nationwide in retail stores and through mail orders.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel